corticotropin-releasing

Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain.

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that releases ACTH from the anterior pituitary, stimulates the sympathetic nervous system and adrenal medulla, reduces hyperpolarizations, and acts as a functional antagonist of inflammatory mediators.

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

Corticotropin-releasing hormone (CRH) is a peptide hormone involved in the stress response. It is the primary regulatory peptide of the hypothalamic-pituitary-adrenal (HPA) axis under stress conditions. CRH can be utilized for research in neuroendocrine activities and anxiety-like behaviors.

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist that reduces plasma growth hormone (GH) levels in vivo [1] [2].

α-Helical Corticotropin Releasing Factor (12-41), a 30-amino-acid α-helical analogue of corticotropin releasing factor/hormone (CRF), is a hypothalamic hormone that promotes adrenocorticotrophic hormone (ACTH) secretion. This compound counteracts CRF's stimulatory effect on ACTH secretion [1] [2].

[DPro5] Corticotropin Releasing Factor, human, rat, a selective R2 agonist of corticotropin-releasing factor/hormone (CRF), is a hypothalamic hormone that prompts the release of adrenocorticotropic hormone (ACTH) and β-endorphin. Unlike typical agents, it does not induce anxiogenic effects but instead influences learning and memory processes in rats [1].

Corticotropin Releasing Factor, ovine [Met(O)21], is a hypothalamic hormone isolated from ovine hypothalamic extracts. It functions by stimulating the secretion of adrenocorticotrophic hormone (ACTH) [1].

[Tyr^0] Corticotropin Releasing Factor, ovine, is a hypothalamic hormone sourced from sheep that prompts the secretion of adrenocorticotropic hormone (ACTH) and β-endorphin [1] [2].

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

Emicerfont is an antagonist of the corticotropin-releasing factor type 1 receptor (IC50: 66 nM).

Pexacerfont (BMS-562086) is a selective antagonist of the corticotropin-releasing factor receptor (IC50: 6.1±0.6 nM for the human CRF1 receptor).

Vasopressin-d5 TFA is the TFA salt form of Vasopressin-d5, an isotopically labeled derivative of Vasopressin. Vasopressin, a cyclic nonapeptide, is synthesized in the medial hypothalamus and plays a critical role in the hypothalamic-pituitary-adrenal axis by enhancing the stimulation of corticotropin-releasing factor, thereby regulating the secretion of adrenocorticotropic hormone. Additionally, Vasopressin acts as a neurotransmitter, exerting its effects through interaction with specific G-protein-coupled receptors.

CRHR1 antagonist 1 (compound 10a) is a non-peptide antagonist of corticotropin-releasing hormone receptor 1 (CRHR1). It serves as a useful tool in the study of psychiatric disorders.

Antalarmin hydrochloride is an antagonist of corticotropin-releasing factor 1(CRF1). Antalarmin hydrochloride produces anti-inflammatory effects and suppresses stress-induced gastric ulceration related to irritable bowel syndrome.

corticotropin-releasing factor1 (CRF1) receptor antagonist

corticotropin-releasing factor receptor 1 (CRF1) antagonist

JTC-017 is an antagonist of Corticotropin-releasing hormone receptor 1.

NGD9002 is a novel generation, topology 2 selective corticotropin releasing factor-1 (CRF-1) receptor antagonist agent.

BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM) that inhibits CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). It is also efficacious in the Defensive Withdrawal model of anxiety in rats and has low in vivo clearance [Cl = 17 mL/min/kg, t½ = 7.8 h].

BMS-764459 is a potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1).